IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

Geode Capital Management LLC raised its stake in shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) by 7.6% in the third quarter, Holdings Channel reports. The institutional investor owned ...

Shares of IGM Biosciences stock opened at $10.31 on Friday. The firm has a market cap of $613.03 million, a price-to-earnings ratio of -2.83 and a beta of 0.08. The business has a 50-day moving ...

Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies MOUNTAIN VIEW, Calif., Nov. 04 ...